Immunic AG
- Country
- ๐ฉ๐ชGermany
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
48
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)โข Click on a phase to view related trials
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: IMU-838 tabletsDrug: Placebo matching IMU-838 tablets
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 1050
- Registration Number
- NCT05201638
- Locations
- ๐บ๐ธ
HonorHealth Research Institute - Bob Bove Neuroscience Institute, Scottsdale, Arizona, United States
๐บ๐ธNeuro of Central Florida, Altamonte Springs, Florida, United States
๐บ๐ธHealthcare Innovations, Coral Springs, Florida, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: IMU-838 tabletsDrug: Placebo matching IMU-838 tablets
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 1050
- Registration Number
- NCT05134441
- Locations
- ๐บ๐ธ
Xenoscience, Inc., 21st Century Neurology, Phoenix, Arizona, United States
๐บ๐ธBradenton Research Center, Bradenton, Florida, United States
๐บ๐ธReliant Medical Research, LLC, Miami, Florida, United States
IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 18
- Registration Number
- NCT05124795
- Locations
- ๐ฌ๐ง
Institute of Cancer Research, London, United Kingdom
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo matching IMU-838
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 450
- Registration Number
- NCT05054140
- Locations
- ๐บ๐ธ
Dr. Sonia Kalirao, Coral Springs, Florida, United States
๐บ๐ธCollier Neurologic Specialists, Naples, Florida, United States
๐บ๐ธProf. James Scott, Ormond Beach, Florida, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Immunic AG
- Target Recruit Count
- 234
- Registration Number
- NCT04379271
- Locations
- ๐ง๐ฌ
Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria
๐ง๐ฌUMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria
๐ฉ๐ชUniversity Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany
- Prev
- 1
- 2
- Next